Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients
Description
CONCLUSION: Among adults who were hospitalised with SARS-CoV-2 infection, azvudine was noninferior to paxlovid in terms of time to sustained clinical recovery, death rates, hospitalization time and cost, with few safety concerns.
